Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 301012 in Heterozygous Familial Hypercholesterolemia
NCT00281008Phase 2Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Feb 2006
- Primary completion
- Jul 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 2 trial of mipomersen in familial hypercholesterolemia (FH), sponsored by Kastle Therapeutics LLC. Started Feb 2006; status: completed.
02
Drugs
mipomersen
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT00281008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281008.